Obstructive Airway Diseases : Role of Lipid Mediators book cover
1st Edition

Obstructive Airway Diseases
Role of Lipid Mediators

ISBN 9781138374454
Published September 18, 2018 by CRC Press
381 Pages 78 B/W Illustrations

SAVE ~ $13.99
was $69.95
USD $55.96

Prices & shipping based on shipping country


Book Description

Incidences of inflammatory airway diseases are on the rise across the world. Existing therapeutic options are ineffective, unsafe, and expensive, and severe cases are nonresponsive to conventional therapy. Therefore, it is imperative that research be undertaken to discover new treatment options. Obstructive Airway Diseases: Role of Lipid Mediators discusses clinically successful and potential lipid targets that can make a difference in treating some of the most intractable disease states.

Topics discussed include:

  • Obstructive airway diseases, etiology, pathophysiology, and existing therapeutic options
  • What constitutes a lipid and how it is broken down to generate biologically active mediators
  • The role of enzymes in the process of lipid mediator synthesis
  • The biology of arachidonic acid, platelet-activating factor, and lysophosphatidic acid and the role they play in airway inflammation
  • Products of arachidonic acid metabolism such as leukotrienes, prostaglandins, epieicosatrienoic acid, and oxoeicosatetraenoic acid
  • Proresolution lipid mediators in inflammatory airway disease conditions
  • The role of sphingosine and ceramide in inflammatory airway disease
  • Protein kinases activated by lipid mediators and those that trigger the generation of lipid messengers

The combined input of a panel of international authorities on lipid mediators makes this volume a valuable resource for all those involved in researching, teaching, and studying airway inflammation as well as those involved in drug discovery research.

Punit Srivastava maintains a blog with additional information about the book and his work.

Table of Contents

Obstructive Airway Diseases: Epidemiology, Etiology, and Therapeutic Options
Abhijit Ray
Lipids: Reservoir of Drug Targets
Abhijit Ray and Punit Kumar Srivastava
Phospholipase A2 as a Potential Drug Target for Airway Disorders
Yoshitaka Taketomi and Makoto Murakami
5-Lipoxygenase Pathway: A Validated Route to Drug Discovery
Carlo Pergola and Oliver Werz
Leukotriene Receptor Antagonists and FLAP Inhibitors
Suman Gupta and Sanjay Malhotra
EETs and Oxo-ETE in Airway Diseases
Jun Yang, Hua Dong, and Bruce D. Hammock
The Eosinophil Chemoattractant 5-Oxo-ETE
William S. Powell and Joshua Rokach
Cyclooxygenases and Prostaglandin Receptors
Jitesh P. Iyer, Jitendra Anant Sattigeri, and Sunanda Ghosh Dastidar
Proresolution Mediators of Inflammation in Airway Diseases: Resolvins Pave New Directions
Bruce D. Levy and Charles N. Serhan
Platelet-Activating Factor Antagonist Therapy for Airway Disorders
Punit Kumar Srivastava, Kent E. Pinkerton, and Rishabh Dev
Lysophosphatidic Acid in Airway Inflammation
Yutong Zhao and Viswanathan Natarajan
Sphingolipids in Airway Inflammation
Sameer Sharma and Carole A. Oskeritzian
Protein Kinase C Isozymes and Airway Inflammation
Puneet Chopra, V. Senthil, and Manish Diwan
Prospects for PI3 Kinase Signaling Inhibition in Obstructive Airway Diseases
Kazuhiro Ito and Nicolas Mercado

View More



Abhijit Ray has worked in human trials with molecules designed to treat airway inflammation associated with asthma and COPD and has published more than 60 articles in peer-reviewed journals. He has been the senior director and head of biology research at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. As a member of the drug discovery team, he manages a group of 60 scientists engaged in discovery research for drugs in the areas of infectious and inflammatory diseases.

Punit Srivastava has been a group leader of biology at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. He was a member of the drug discovery group of Ranbaxy Laboratories Ltd. from 2004 to June 2010 and has worked for more than six years in drug discovery research, which has resulted in one molecule entering human trial for COPD. He has published more than 15 articles in peer-reviewed journals and filed at least six patents. As a member of the drug discovery team at Daiichi Sankyo, he is leading projects in the area of inflammation.